For people fighting advanced lung cancer, time is the most precious thing of all — and a new medicine just handed many of them an extra eight months. A drug called ivonescimab helped patients live a median of 30.8 months, compared with 22.6 months for those on the standard treatment pembrolizumab. That difference is not luck. It is a statistically meaningful survival benefit, announced at the IASLC 2026 World Conference on Lung Cancer by researchers in China.
Lung cancer remains one of the world's deadliest cancers, in large part because so many cases are found only after the disease has already spread. For decades, the first line of defense was chemotherapy, a treatment that works but takes a heavy toll on the body. That is why this result matters: ivonescimab is a chemotherapy-free option for a specific group of patients — those whose tumors carry a protein marker called PD-L1. It works by joining two different weapons into one antibody, attacking the cancer from two angles at once. In plain terms, it keeps the immune system's foot on the gas while also blocking a signal the tumor uses to hide.
The evidence comes from a phase 3 trial called HARMONi-2, which enrolled 398 patients across China between November 2022 and August 2023. Half received ivonescimab and half received pembrolizumab, the current standard. The difference in living longer was seen across many groups of patients, but it was especially large in those with high PD-L1 levels and in those with a subtype of the disease called squamous lung cancer. Along the way, the drug also slowed the cancer's growth: patients stayed stable for a median of 11.1 months on ivonescimab versus 5.8 months on the standard drug.
Safety was broadly similar between the two groups. Side effects were common in both — as they are with most cancer drugs — but serious ones were manageable, and similar shares of patients in each group stopped treatment because of them. Dr. Caicun Zhou of Shanghai East Hospital, who led the work, said the results "further strengthen ivonescimab as a chemotherapy-free first-line option."
Because the earlier results were so strong, ivonescimab was already approved in China in April 2025. This new survival data cements it as a standard-of-care therapy there. The question now is whether the rest of the world will follow. For families facing a lung cancer diagnosis, every additional month matters — and this drug just bought them eight. The next step is bringing that hope beyond China's borders, one clinical trial and one approval at a time.